Cheng Hu Email & Phone Number

California, United States

Sevenoaks, Gb

Ie

Advise companies on developing ML models for ADMET prediction, structure based pKi predictions,and GenerativeAI de novo small molecules discovery;Advise startup biotech companies on implementation of AI workflows to identify novel chemotypes,expedite hit2lead and LO, and de-risk pre-clinical and clinical development.

San Francisco, California, Us

Molecular Design and Drug Development (M3D)- Delivered best-in-class systemic and first-in-class gut-restricted RIPK2 advanced candidates for IBD- Launched the design and synthesis of two hit to lead projects (undisclosed oncology/immunology targets)- Led multiple AI enabled HitID, HitExpansion, Hit2Lead and LeadOptimization drug discovery projects;- Contributed to the identification and prioritization of projects to build a portfolio of drug discoveryprojects.AI Drug Discovery Tool Development:- Acted as medicinal chemistry/DMPK representative on the weekly AIDD model development meeting- Advised ML models development and launched ADMETwise for internal and collaborative drug discovery projects- Led the integration of ADMETwise and Structure-based pKi prediction into the automatic moleculedesign/synthesis/test/analysis workflow- Built the practical use cases of AI application in drug discovery process for BD purposes

South San Francisco, California, Us

Medicinal chemistry lead for RIPK1, DLK and NLRP3 projects

San Francisco, Ca, Us

Project Leader. Led a Hit to Lead project team of 7 external and internal chemists. Starting from micro-molar range HTS hits, several series of chemotypes were optimized to compounds with low nano-molar affinity and good physico-chemical properties, guided by MD simulation, crystallography data and my medicinal chemistry instincts developed over the years.

Basel, Baselstadt, Ch

Proposed and developed 2 novel inhibitors series featuring sp3 rich and low clogP;Identified a “methyl pocket” to improve kinase specificities;Established a novel synthesis route (shorten from 10 steps to 6 steps) to target compounds. Established synthesis route to map out SAR on 2 chemotype, improved a key buchwald reaction step yield from under 5% to 65% by ligand screening and application of novel precatalystIdentified “sweetspot” region of ClogP, PKa, PSA to design compounds addressing efflux, HERG issues; Proposed and demonstrated alternative synthesis route to quickly mapping of SAR.Scaled up synthesis of lead compound for PK/PD and animal studiesProposed and synthesized a chiral intermediate by increasing chirality to facilitate diastereomer separation

San Carlos, California, Us

Developed enantioselective synthesis route of an emerging chemotype, which led to quick identification of C5a clinical trial compound Avacopan.

上海, 上海, Cn

Bachelor Of Science, Chemistry

Master Of Engineering, Fine Chemicals